(Q37790212)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20852268%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

title

Integrase inhibitors in the treatment of HIV-1 infection (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20852268%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20852268%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

author name string

William G Powderly

series ordinal

1

1 reference

23 August 2017

language of work or name

English

0 references

publication date

18 September 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20852268%20AND%20SRC:MED&resulttype=core&format=json

Journal of Antimicrobial Chemotherapy

14 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20852268%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

volume

65

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20852268%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20852268%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

page(s)

2485-2488

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20852268%20AND%20SRC:MED&resulttype=core&format=json

Structure and function of HIV-1 integrase

14 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKQ350

HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKQ350

Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKQ350

Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKQ350

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKQ350

Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKQ350

Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKQ350

Virologic outcomes of changing enfuvirtide to raltegravir in HIV-1 patients well controlled on an enfuvirtide based regimen: 24-week results of the CHEER study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKQ350

Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKQ350

Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKQ350

A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKQ350

Genotypic and phenotypic resistance patterns at virological failure in a simplification trial with nevirapine, efavirenz or abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKQ350

Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKQ350

Evolution of integrase resistance during failure of integrase inhibitor-based antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKQ350

Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKQ350

21 January 2018

Identifiers

DOI

10.1093/JAC/DKQ350

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20852268%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

1 reference